SOL-101

N/A

Report date: 2025/01/26 17:05:50
NME

Base Information

Drug NameSOL-101
Drug Alias NameSOL-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action70-kDa ribosomal protein S6 kinases inhibitors
Targets70-kDa ribosomal protein S6 kinases
Therapy Area/IndicationsFragile X Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSentinel Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSentinel Oncology Ltd
Inactive CompaniesN/A
Active IndicationsFragile X Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A